Sign up for free shipping on all website orders, no minimum required, and get exclusive coupons!
TCI offers bulk solutions for a wide range of chemical reagents. Get a Quote for Your Bulk Chemical Requirements.
Maximum quantity allowed is 999
The Institute of Glycotechnology of Tokyo Chemical Industry Co., Ltd. (TCI), Group Leader Fumiaki Nakayama and Dr. Taichi Miura of the Regenerative Therapy Research Group, Department of Radiation Regulatory Science Research, National Institute of Radiological Sciences (NIRS) have discovered a new function of the highly sulfated hyaluronic acid commercialized by TCI. It provides protection against intestinal damage and does not induce bleeding. Its expected application will be in the development of drugs that prevent damage caused by radiotherapy to the intestinal tract and other parts of the body.
Like heparin, hyaluronic acid is a polysaccharide classified as a glycosaminoglycan. Sulfated hyaluronic acid has already been reported to bind to fibroblast growth factor (FGF) 2 and others. Additionally, it has been used in maintaining the induced pluripotent stem (iPS) cells in an undifferentiated state. TCI has developed and commercialized a technology for the large-scale production of sulfated hyaluronic acid using a technology for the high-precision sulfation of hyaluronic acid. (highly sulfated hyaluronic acid; Product Number: H1739)
HA-LS showed weaker binding capability than heparin and HA-HS showed stronger binding capability than heparin.
Various radiotherapy protection methods have been investigated in previous studies, and FGF1 has been examined for its protective effect on the small intestine against radiation damage. Heparin is said to stabilizes the FGF1 structure, resulting in a highly protective effect. However, heparin inhibits blood coagulation and promotes bleeding, making it difficult to use in patients with radiological intestinal disorders at the risk of excess bleeding. Therefore, we need to develop a drug that can stabilize the structure of FGF1 without promoting bleeding.
The Regenerative Therapy Research Group studied the protective action of highly sulfated hyaluronic acid on the degradation of growth factors and evaluated its efficacy against radiological damage to the intestinal tract. The sulfated hyaluronic acid was as effective as the combination of FGF1 and heparin. Furthermore, highly sulfated hyaluronic acid had limited blood anticoagulant activity. These results indicate that highly sulfated hyaluronic acid is a promising radioprotective agent associated with a low risk of bleeding that prevents the induction of hemorrhage, which is an issue concerned with the combination of FGF1 and heparin.
The research was published in the online edition of Advances in Radiation Oncology, a scientific journal published by the American Society for Radiation Oncology, on March 13, 2022.
TCI will continue to develop a joint research effect to broaden the application of this material in various fields. Additionally, we are open to consulting with developers on the degree of sulfation, molecular weight, and further modifications according to their requirements.